Seattle, WA -- (SBWIRE) -- 11/11/2019 -- Currently, majority of the biological products are administered through parental route of administration. However, oral biologics represent a novel category of drugs, which is gaining traction in the last few decades. Moreover, major players in the market are working for the development of oral biologics and launch them in market, however, major concern regarding oral biologics is to protect the protein from degradation and digestion in the gastrointestinal tract.
Hence, such robust research and development activities by key players is expected to create a conducive environment and support global oral biologics market growth over the forecast period.
The global oral biologics market size was valued at US$ 834.3 Mn in 2018, and is expected to witness a CAGR of 32.8% during the forecast period (2018 – 2026).
Request a sample copy of this report @ https://www.coherentmarketinsights.com/insight/request-sample/989
Major companies in the market are involved in various strategies such as research and development, which is expected to drive growth of the global oral biologics market during the forecast period. For instance, in February 2019, researchers at Massachusetts Institute of Technology (MIT) developed a drug capsule with the potential to deliver an oral insulin named SOMA capsule, thereby replacing (or eliminating) the need to administer insulin via injections multiple times a day for patients with type 1 diabetes. The researchers stated that the drugs is currently under preclinical studies and is expected to enter clinical trials by 2022.
The research was funded by Novo Nordisk, the National Institutes of Health, a National Science Foundation Graduate Research Fellowship, Brigham and Women's Hospital, a Viking Olaf Bjork Research Scholarship, and the MIT Undergraduate Research Opportunities Program.
Key companies in the market are involved in strategic partnerships and collaborations, in order to gain edge in the market, which in turn, is expected to drive the market growth in the near future.
For instance, in 2016, Rani Therapeutics collaborated with Medimmune, a research and development subsidiary of AstraZeneca, to evaluate Rani Therapeutics' novel oral drug delivering platform. This collaboration is expected to facilitate feasibility studies of drugs and test biologic molecules in the area of metabolic disease, to evaluate oral delivery of molecules. The objective of this collaboration is to deliver biologics orally, in order to increase compliance and improve patients' lives globally.
For more information, see Download PDF Copy Here @ https://www.coherentmarketinsights.com/insight/request-pdf/989
Key players in the market are focusing on gaining the U.S. Food and Drug Administration (FDA) approval for their oral biologics and launch them in the market. For instance, in March 2019, Novo Nordisk A/S submitted two New Drug Applications (NDAs) to the U.S. Food and Drug Administration (FDA) for oral semaglutide, the once-daily glucagon-like peptide-1 (GLP-1) receptor agonist in a pill.
According to Labiotech.eu, 2018, around half of the top 100 drug sales will be biologics by 2022. Moreover, around 2,700 biologics are currently in development, which means they can create a conducive biologics market post approval. However, the biological drugs are administered parentally, which can result in high treatment costs and lower adherence rates.
According to the research conducted by Rani Therapeutics in 2018, around 62% patients and 86% physicians reported that patients either skip their injection or consistently fail to inject the drug as prescribed. The research further stated that around 70% rheumatologists and 92% gastroenterologists believe that availability of pills would significantly increase patient compliance rates.
Thus, the availability of biologics in the form of oral pills is expected to increase compliance rate and patient comfort, which can significantly improve the patients' health by changing the course of the disease and preventing further complications. Moreover, oral biologics could also lower medication costs and improve access while improving the health of millions with chronic diseases globally.
Request for Customization @ https://www.coherentmarketinsights.com/insight/request-customization/989
The U.S. Food and Drug Administration (FDA) issues guidelines and regulates biologics including: vaccines, blood and blood products, cellular and gene therapy products tissue and tissue products, and allergenics.
The Center for Biologics Evaluation and Research (CBER) is a part of the U.S. FDA that regulates biological products for human use, under applicable federal laws, including the Public Health Service Act and the Federal Food, Drug, and Cosmetic Act.
CBER supports manufacturers to use appropriate standards in the development of medical products. The use of appropriate standards can facilitate product development and provide a more efficient evaluation of regulatory submissions, including investigational new drug applications (INDs), biologics license applications (BLAs), new drug applications (NDAs), investigational device exemptions (IDEs), premarket approval applications, and premarket notifications, supplements, and amendments.
Key players operating in the global oral biologics market include Novo Nordisk A/S, Biocon Limited, Oramed Pharmaceuticals, Inc., Rani Therapeutics, Entera Bio Ltd., Allergan plc, Emisphere Technologies, Inc., Enteris BioPharma, Inc., Chiasma, Inc., and Allena Pharmaceuticals, Inc.
About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.